Premium
Influence of age on visual results of intravitreal bevacizumab for myopic choroidal neovascularization
Author(s) -
KORT F,
CHEBIL A,
BOULADI M,
BOURAOUI R,
BEN YOUSSEF N,
MERDASSI A,
EL MATRI L
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.275.x
Subject(s) - medicine , choroidal neovascularization , ophthalmology , bevacizumab , visual acuity , retinal , macular degeneration , surgery , chemotherapy
Purpose To evaluate the influence of age on the visual and anatomic outcome of myopic patients with choroidal neovascularization (CNV) treated with intravitreal bevacizumab (IVB). Methods Review of retrospectively collected data of 52 eyes in 50 patients with myopic CNV treated with IVB injections (1.25 mg/ 0.05ml). According to the age at onset of CNV, patients were divided into 2 groups: A younger group (< 50 years); (n=25, 27 eyes) and an older group (≥ 50 years); (n=25, 25 eyes). Best corrected visual acuity (BCVA) and central retinal thickness (CRT) measured with optical coherence tomography (OCT) were compared between the two groups over 12 months. Results The mean number of IVB injections was 1.8 in the younger group and 2.0 in the older group. In the younger group, mean BCVA improved from 1.32 logMAR at baseline to 0.77 logMAR at 12 months (p=.002). In the older group, BCVA improved from 1.0 logMAR to 0.84 logMAR at 12 moths (p=.035). There was a mean of 5.1 lines improvement in BCVA from baseline in the younger group versus a mean of 2.2 lines improvement in the older group (p<.05). Decrease in mean CRT was significantly higher in the younger group than in the older one at 12 months: 114.02µm and 68.8µm respectively (p=.003). Conclusion Visual prognosis of myopic CNV treated with IVB seems to be better in patients younger than 50 years.